FEATURES OF THE DEVELOPMENT OF A LYOPHILIZED INJECTABLE DOSAGE FORM OF THE ORIGINAL ANTICANCER DRUG LCS-1208
DOI:
https://doi.org/10.22159/ijap.2021v13i4.41371Keywords:
Lyophilization, LCS-1208, Freeze-drying, Lyophilisate for parenteral useAbstract
Objective: Development of a lyophilized injectable dosage form LCS-1208, an original antitumor drug based on an indolocarbazole derivative.
Methods: The prepared solution of the injectable dosage form LCS-1208 is transferred to sterilizing filtration, which is carried out under vacuum on a «Stericup» filter unit with a filter pore size of 0.22 μm. The sterile solution of the injectable dosage form LCS-1208 is poured into sterile vials using a dispenser and lyophilized in a freeze-drying chamber. At the end of drying, the preparation is corked in the chamber of a sublimation unit using a hydraulic device and transferred to crimping with aluminum caps using a seaming machine. Quantitative determination of the drug content was determined by spectrophotometry using a standard sample at λ = 320±2 nm. The pH was determined by potentiometry.
Results: A freeze-drying regimen for the injectable dosage form LCS-1208 has been developed. The required solution freezing temperature was established taking into account the presence of 2 eutectic zones: a solution of LCS-1208 in DMSO (-35 ÷-32) °С, an aqueous solution of Kollidon 17PF (-10 ÷-8) °С. As a result of a series of experiments, the optimal lyophilization regime was chosen that does not require preliminary freezing in a low-temperature chamber, with freezing on the shelves of freeze-drying at a temperature of-47 °C without their preliminary cooling. The most acceptable vial filling volume was determined, amounting to 3 ml, and the rate of temperature rise during secondary drying of the preparation was justified. When using the developed regime of lyophilization of the LCS-1208 solution, it was shown that it can be sublimated while preserving the initial qualitative and quantitative characteristics.
Conclusion: In this article, using the example of creating a lyophilized injectable dosage form LCS-1208 (the original antitumor drug from the indolocarbazole group), the main problems that arose during the lyophilization of the selected composition of the model solution, as well as ways to improve the process.
Downloads
References
Blynskaya EV, Tishkov SV, Alekseev KV. Technological approaches to improving the process of lyophilization of protein and peptide drugs. Russ J Biother 2017;16:6-11.
Carpenter JF, Chang BS, Garzon Rodriguez W, Randolph TW. Rational design of stable lyophilized protein formulations: theory and practice. In: Carpenter JF, Manning MC. editors. Rational design of stable protein formulations. Pharmaceutical Biotechnology. Vol 13. Springer, Boston, MA; 2002. https://doi.org/10.1007/978-1-4615-0557-0_5
Tang XC, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res 2004;21:191-200.
Gulyakin ID, Nikolaeva LL, Dmitrieva MV. Obtaining and analysis of the lyophilized dosage form LCS-1208 by thin-layer chromatography and spectrophotometry. Drug Dev Reg 2016;17:62-7.
Chang LL, Shepherd D, Sun J. Mechanism of protein stabilization by sugars during freeze‐drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J Pharm Sci 2005;94:1427-44.
Arshinova OYu, Oborotova NA, Sanarova EV. Excipients in the technology of lyophilization of drugs. Drug Dev Reg 2013;2:20-5.
Chang BS, Patro SY. Freeze-drying process development for protein pharmaceuticals. In: Costantino HR, Pikal MJ. editors. Lyophilization of biopharmaceuticals. American Association of Pharmaceutical Scientists, Arlington; 2004. p. 113-8.
Klochkova TI, Shprakh ZS. Organization, scaling and optimization of the production of lyophilized preparations. Russ J Biother 2006;5:115-22.
Overcashier DE, Patapoff TW, Hsu CC. Lyophilization of protein formulations in vials: Investigation of the relationship between resistance to vapor flow during primary drying and small‐scale product collapse. J Pharm Sci 1999;88:688-95.
Searles JA, Carpenter JF, Randolph TW. Annealing to optimize the primary drying rate, reduce freezing‐induced drying rate heterogeneity, and determine Tg′ in pharmaceutical lyophilization. J Pharm Sci 2001;90:872-87.
Arshinova O Yu, Sanarova EV, Lantsova AV. Lyophilization of liposomal drug forms (review). Pharm Chem J 2012;46:29-34.
Hottot A, Vessot S, Andrieu J. Freeze-drying of pharmaceuticals in vials: influence of freezing protocol and sample configuration on ice morphology and freeze-dried cake texture. Chem Eng Proc: Process Intensification 2007;46:666-74.
Liu J. Physical characterization of pharmaceutical formulations in frozen and freeze-dried solid states: techniques and applications in freeze-drying development. Pharm Dev Technol 2006;11:3-28.
Kiseleva MP, Shprah ZS, Borisova LM. Preclinical study of indolocarbazole N-glycosides derivative LCS-1208 antitumor activity. Report I. Russ J Biother 2015;14:71-7.
Kiseleva MP, Shprah ZS, Borisova LM. Preclinical study of the antitumor activity of indolocarbazole N-glycosides derivative of LCS-1208. Report II. Russ J Biother 2015;14:41-8.
Nikolina AA, Kul’Bachevskaya NYu, Konjaeva OI. Study of acute toxicity of novel antitumor preparation based on derivative of indolocarbazole–LCS-1208. Russ J Biother 2015;14:59-64.
Nikolina AA, Kul’Bachevskaya NYu, Konjaeva OI. Research of subchronic toxicity in rats of glycoside derivative of indolocarbazole LCS-1208. Russ J Biother 2016;15:62-9.
Published
How to Cite
Issue
Section
